Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …

Gastric cancer is the fifth most common cancer and the third most common cause of cancer
death globally. Risk factors for the condition include Helicobacter pylori infection, age, high …

Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate
consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a …

Summary Background Approximately 15–20% of advanced gastric and gastro-oesophageal
junction cancers overexpress HER2. In DESTINY-Gastric01, the HER2-targeted antibody …

PURPOSE To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human
epidermal growth factor receptor 2 (HER2)–low gastric or gastroesophageal junction (GEJ) …

PURPOSE Trastuzumab is the only approved targeted drug for first-line treatment of human
epidermal growth factor receptor 2–positive (HER2+) metastatic gastric cancer (mGC) …

Background Although discordance in HER2 positivity between primary and metastatic
lesions is well established, changes in HER2 positivity after anti-HER2 therapy have not …

PURPOSE Trastuzumab-containing chemotherapy is the recommended first-line regimen for
human epidermal growth factor receptor 2 (HER2)–positive advanced gastric or …

Gastric cancer (GC) represents a leading cause of cancer related morbidity and mortality
worldwide accounting for more than 1 million of newly diagnosed cases and thousands of …

Molecular targeted therapy of cancer has always been the focus of clinicians. Among those
therapeutic targets, the human epidermal growth factor receptor-2 (HER-2) signaling …